MolPharm Over 1500 Individual Drug Articles!

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Molecular Pharmacology Fast Forward
First published on November 1, 2007; DOI: 10.1124/mol.107.041236

0026-895X/08/7302-338-348$20.00
Mol Pharmacol 73:338-348, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.041236v1
73/2/338    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Related articles in MolPharm
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Emanuel, S. L.
Right arrow Articles by Greenberger, L. M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Emanuel, S. L.
Right arrow Articles by Greenberger, L. M.

Cellular and in Vivo Activity of JNJ-28871063, A Nonquinazoline Pan-ErbB Kinase Inhibitor That Crosses the Blood-Brain Barrier and Displays Efficacy against Intracranial Tumors

Stuart L. Emanuel, Terry V. Hughes1, Mary Adams2, Catherine A. Rugg3, Angel Fuentes-Pesquera3, Peter J. Connolly4, Niranjan Pandey5, Sandra Moreno-Mazza3, Jeannene Butler6, Virna Borowski7, Steven A. Middleton8, Robert H. Gruninger, Jennifer R. Story, Cheryl Napier, Beth Hollister, and Lee M. Greenberger9

Cancer Therapeutics Research, Johnson & Johnson Pharmaceutical Research & Development, Raritan, New Jersey (S.L.E., T.V.H., M.A., C.A.R., A.F.P., P.J.C., N.P., S.M.M., J.B., V.B., S.A.M., R.H.G., L.G.) and Piedmont Research Center, Morrisville, North Carolina (J.R.S., C.N., B.H)

JNJ-28871063 is a potent and highly selective pan-ErbB kinase inhibitor from a novel aminopyrimidine oxime structural class that blocks the proliferation of epidermal growth factor receptor (EGFR; ErbB1)- and ErbB2-overexpressing cells but does not affect the growth of non-ErbB-overexpressing cells. Treatment of human cancer cells with JNJ-28871063 inhibited phosphorylation of functionally important tyrosine residues in both EGFR and ErbB2 and blocked downstream signal transduction pathways responsible for proliferation and survival. A single dose of compound reduced phosphorylation of ErbB2 receptors in tumor-bearing mice, demonstrating target suppression in vivo. Tissue distribution studies show that JNJ-28871063 crosses the blood-brain barrier and penetrates into tumors, where it is able to accumulate to higher levels than those found in the plasma. JNJ-28871063 showed oral antitumor activity in human tumor xenograft models that overexpress EGFR and ErbB2. In an intracranial ErbB2-overexpressing tumor model, JNJ-28871063 extended survival relative to untreated animals. The brain is a primary site of metastasis for EGFR-overexpressing lung cancers and ErbB2-overexpressing breast cancers. Therefore, the ability to penetrate into the brain could be an advantage over existing therapies such as trastuzumab (Herceptin) and cetuximab (Erbitux), which are antibodies and do not cross the blood-brain barrier. These results show that JNJ-28871063 is orally bioavailable, has activity against EGFR and ErbB2-dependent tumor xenografts, and can penetrate into the brain and inhibit ErbB2-overexpressing tumor growth.

Received August 25, 2007; accepted November 1, 2007

Address correspondence to: Stuart Emanuel, Bristol-Myers Squibb, Oncology Drug Discovery, Princeton, NJ 08543. E-mail: stuart.emanuel{at}bms.com.


Related articles in MolPharm:

Revoking the Privilege: Targeting HER2 in the Central Nervous System
Joseph N. Contessa and Daniel A. Hamstra
MolPharm 2008 73: 271-273. [Abstract] [Full Text]  





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics